Yokohama to Host WCN’26: The World Congress of Nephrology Returns to Japan After 36 Years
The World Congress of Nephrology 2026 (WCN’26), the flagship event of the International Society of Nephrology (ISN), is set to take place in Yokohama from March 28 to 31, 2026. The Congress is co-hosted by the Japanese Society of Nephrology (JSN) and the Asian Pacific Society of Nephrology (APSN).
The Yokohama City Visitors Bureau (YCVB) and PACIFICO Yokohama, in collaboration with the City of Yokohama, supported the bid led by Professor Masaomi Nangaku, President of the Japanese Society of Nephrology. Thanks to PACIFICO Yokohama’s excellent track record in hosting international conferences and the venue’s excellent accessibility, the bid was successfully secured.
Marking a highly anticipated return to Japan after 36 years, the prestigious WCN will bring together leading experts, researchers, and healthcare professionals dedicated to advancing kidney health worldwide. Through dynamic scientific discussions, high-level collaborations, and knowledge exchange, WCN’26 will accelerate advancements in kidney care and strengthen international partnerships.
Comment from Conference Chair, Professor Masaomi Nangaku
“We are thrilled that Yokohama has been chosen as the venue for the World Congress of Nephrology 2026. With its excellent accessibility and convenient hotels, shopping, and conference facilities, Yokohama is the perfect location to promote global collaboration in nephrology research and clinical practices, while further elevating the international presence of the Japanese Society of Nephrology.”
Event Overview
- Event Name: World Congress of Nephrology 2026 (WCN’26)
- Dates: March 28–31, 2026
- Venue: PACIFICO Yokohama
- Expected Attendance: 5,000 participants (including 2,000 from overseas)
- Organizer: International Society of Nephrology (ISN) https://www.theisn.org/
-
Previous and Future Conferences:
2025: New Delhi, India
2024: Buenos Aires, Argentina
2023: Bangkok, Thailand + Virtual
2022: Kuala Lumpur, Malaysia + Virtual
Through their support of international conferences like WCN’26, YCVB and PACIFICO Yokohama are working to boost economic development and foster new business opportunities in the region.
About the Yokohama City Visitors Bureau:
The role of the Yokohama City Visitors Bureau (YCVB) is to employ the wealth of resources existing in the City of Yokohama and Kanagawa Prefecture to promote the region as an ideal destination for both tourists and international conventions. In this way, the YCVB is contributing to the reinvigoration of the City of Yokohama and surrounding areas, and the advancement of its globalization.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326550042/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend30.4.2025 08:00:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalificat
SES: Q1 2025 Results30.4.2025 07:30:00 CEST | Press release
Solid Start to the Year SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including pr
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 03:00:00 CEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 22:03:00 CEST | Press release
A Year of Broad-Based Sales Growth, Expanded Market Share and Increased Profitability, Driven by Strategic Priorities SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases.
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 21:32:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom